Seventeen research firms currently cover Jazz Pharmaceuticals, assigning the company an average recommendation of Moderate Buy. Within this group, analysts’ views span from Sell to Buy: one firm recommends selling, three recommend holding, and thirteen advocate buying the stock. This distribution underscores broad confidence in Jazz’s medium-term outlook, while highlighting a minority of cautious voices.

Over the past quarter, multiple brokerages updated their outlooks on Jazz Pharmaceuticals. JPMorgan Chase & Co. reduced its target, maintaining an Overweight rating. Truist Financial increased its target and reiterated a Buy rating. Wall Street Zen upgraded its assessment to Strong Buy. Robert W. Baird raised its target and assigned an Outperform rating, and Royal Bank of Canada likewise affirmed an Outperform stance.

Company insiders have been net sellers in recent months. A board director reduced her holdings by approximately 14%, while the chief accounting officer trimmed her position by nearly 40%. In total, insiders disposed of more than 120,000 shares during the last quarter, reflecting a modest de-risking of personal portfolios against Jazz stock.

Jazz Pharmaceuticals remains institutionally held, with roughly 89% owned by major investors and hedge funds. Notable shifts include a 9% uptick in holdings by a wealth advisory group, small increases of 1.5% to 0.4% by various asset managers, and a near 1% rise by a state teachers’ retirement system. These incremental moves suggest sustained institutional conviction in Jazz’s long-term strategy.